MX2016006179A - Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso. - Google Patents

Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.

Info

Publication number
MX2016006179A
MX2016006179A MX2016006179A MX2016006179A MX2016006179A MX 2016006179 A MX2016006179 A MX 2016006179A MX 2016006179 A MX2016006179 A MX 2016006179A MX 2016006179 A MX2016006179 A MX 2016006179A MX 2016006179 A MX2016006179 A MX 2016006179A
Authority
MX
Mexico
Prior art keywords
capsaicinoid
formulations
methods
administration
manufacture
Prior art date
Application number
MX2016006179A
Other languages
English (en)
Inventor
Daniel Bucks
Philip J Birbara
A Birbara Charles
COUGHLIN Mary
Original Assignee
Vizuri Health Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/078,253 external-priority patent/US20140142073A1/en
Application filed by Vizuri Health Sciences Llc filed Critical Vizuri Health Sciences Llc
Publication of MX2016006179A publication Critical patent/MX2016006179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se dan a conocer en este documento formulaciones capsaicinoides y métodos de tratamiento los cuales se pueden utilizar para tratar/atenuar el dolor en mamíferos. Típicamente, la administración es a través de una inyección en un sitio discreto para proporcionar alivio al dolor durante un período de tiempo prolongado. Las formulaciones se administran en un vehículo farmacéuticamente aceptable. Las formulaciones incluyen un agente analgésico en una cantidad suficiente para atenuar los efectos de quemadura e hiperalgésicos de la administración de capsaicinoides. La invención también incluye un método para tratar el dolor por medio de la administración de un corticosteroide seguida por la administración de un capsaicinoide.
MX2016006179A 2013-11-12 2014-11-12 Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso. MX2016006179A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/078,253 US20140142073A1 (en) 2012-11-12 2013-11-12 Aqueous based capsaicinoid formulations and methods of manufacture and use
US14/253,660 US20150133561A1 (en) 2013-11-12 2014-04-15 Aqueous based capsaicinoid formulations and methods of manufacture and use
PCT/US2014/065290 WO2015073577A1 (en) 2013-11-12 2014-11-12 Aqueous based capsaicinoid formulations and methods of manufacture and use

Publications (1)

Publication Number Publication Date
MX2016006179A true MX2016006179A (es) 2016-10-26

Family

ID=53044318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006179A MX2016006179A (es) 2013-11-12 2014-11-12 Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.

Country Status (8)

Country Link
US (2) US20150133561A1 (es)
EP (1) EP3068373B1 (es)
JP (1) JP6782636B2 (es)
KR (1) KR102251124B1 (es)
CN (1) CN105960230B (es)
CA (1) CA2930395A1 (es)
MX (1) MX2016006179A (es)
WO (1) WO2015073577A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041121A1 (en) * 2016-11-02 2018-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof
MX2020000488A (es) 2017-07-20 2020-10-28 Centrexion Therapeutics Corp Metodos y composiciones para el tratamiento del dolor usando capsaicina.
AU2019325407A1 (en) * 2018-08-24 2021-03-18 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of knee joint pain
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
CN113855626B (zh) * 2020-08-07 2023-03-24 北京泰德制药股份有限公司 一种用于骨关节炎治疗的辣椒碱注射剂及其制备方法
CN112691091A (zh) * 2021-01-09 2021-04-23 胡宝贤 低浓度石炭酸的新应用
CN114028540B (zh) * 2021-11-26 2023-10-17 海南鑫开源医药科技有限公司 一种具有镇痛作用的组合物、微针贴片及其制备方法以及应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
JPS63130540A (ja) * 1986-11-18 1988-06-02 Sunstar Inc 鎮痛用組成物
JPH0621063B2 (ja) * 1986-12-06 1994-03-23 サンスタ−株式会社 歯科用鎮痛剤組成物
AU720859B2 (en) 1997-03-13 2000-06-15 James N. Campbell Compositions containing capsaicin or capsaicin analogues and a local anesthetic
JP2002124960A (ja) 2000-10-16 2002-04-26 Link Evolution Corp 通信装置、通信システム、及び、通信方法
ES2311756T3 (es) 2002-12-18 2009-02-16 Algorx Administracion de la capsiacina.
EP1605956B1 (en) 2002-12-18 2015-11-11 Centrexion Therapeutics Corporation Administration of capsaicinoids for the treatment of osteoarthritis
AU2004230915B2 (en) 2003-04-08 2008-08-07 Algorx Pharmaceuticals, Inc. Preparation and purification of synthetic capsaicin
AU2005249572A1 (en) 2004-06-02 2005-12-15 Neurogesx, Inc. Formulations comprising a capsaicinoid a local anesthetic and/or an antipruritic agent for the treatment of pain
CN101119713A (zh) * 2004-11-24 2008-02-06 阿尔高克斯制药公司 类辣椒素凝胶制剂及其用途
JP2008524267A (ja) * 2004-12-22 2008-07-10 メステックス アクチェンゲゼルシャフト バニロイド受容体作用薬と神経再生物質阻害物質との混合物、鎮痛薬を生成するためのそれらの使用、および該鎮痛薬を適用する方法
SI1830835T1 (sl) 2004-12-28 2012-07-31 Mestex Ag Uporaba agonista vaniloidnega receptorja skupaj zglikozaminoglikanom ali proteoglikanom za proizvodnjo agensa za zdravljenje bolečin v sklepih in metoda in apliciranje omenjenega agensa
JP5319278B2 (ja) 2005-05-27 2013-10-16 ロイヤー バイオメディカル， インク． 生体再吸収性ポリマーマトリックス、ならびにその作製および使用方法
US20070098660A1 (en) * 2005-10-27 2007-05-03 Jim Taneri Methods and compositions for epilation
EP1968614A2 (en) * 2005-12-14 2008-09-17 Anika Therapeutics Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
CN103356694B (zh) * 2006-12-06 2015-09-02 生化学工业株式会社 治疗关节炎病症的长效药剂
US8623335B2 (en) * 2007-09-10 2014-01-07 Tauna Ann Waddington Scar and rosacea and other skin care treatment composition and method
US8158682B2 (en) 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
US8637569B2 (en) * 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
AU2013341380B2 (en) * 2012-11-12 2018-04-26 Propella Therapeutics, Inc. Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid

Also Published As

Publication number Publication date
JP6782636B2 (ja) 2020-11-11
KR102251124B1 (ko) 2021-05-13
US20190142948A1 (en) 2019-05-16
KR20160094952A (ko) 2016-08-10
WO2015073577A1 (en) 2015-05-21
EP3068373B1 (en) 2021-06-23
JP2016540830A (ja) 2016-12-28
US20150133561A1 (en) 2015-05-14
CN105960230B (zh) 2022-06-21
EP3068373A1 (en) 2016-09-21
CA2930395A1 (en) 2015-05-21
CN105960230A (zh) 2016-09-21

Similar Documents

Publication Publication Date Title
MX2018013715A (es) Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor.
MX2016006179A (es) Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.
MX2016005532A (es) Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades.
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
BR112016007946A2 (pt) combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2016002479A (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
PH12016502352A1 (en) Pharmaceutical composition
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2015003035A (es) Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual.
TW201613578A (en) Pharmaceutical combinations
PH12017500392A1 (en) Medical treatments based on anamorelin
MY196979A (en) Method of treating disease by auricular anesthesia of cranial nerves
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
MX2015016418A (es) Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
MX2016005614A (es) Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
MX2017003140A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
MX2010013790A (es) Composiciones y metodos para tratar inflamacion de corneas.
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
AR102494A1 (es) Métodos para tratar enfermedades oculares
ZA202202673B (en) Methods and compositions for treating endometriosis
EA032959B9 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции